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Innovations
for Gene
Technologysing the same technology
that drives inkjet printers,
a Kirkland, Washington–based bioinfor-
matics company is developing sophisticat-
ed DNA microarrays that may help
researchers measure and analyze gene
expression faster, more economically, and
with greater precision than ever before
possible. These small glass slides may rev-
olutionize the field of toxicogenomics,
helping scientists target new drugs, dis-
cover gene functions, determine biologic
pathways, and better understand illnesses
such as cancer, cystic fibrosis, and cardio-
vascular disease at the molecular level.
The FlexJet™ system, as the microar-
ray product is known, was pioneered by the
group of scientists who founded Rosetta
Inpharmatics—Stephen Friend, Leland
Hartwell, Leroy Hood, and Jasper Rine—
along with Alan Blanchard, who heads
Rosetta’s FlexJet technology development
team. The system combines modern print-
ing technology with DNA synthesis tech-
niques to print tiny arrays of thousands of
different gene sequences onto a single glass
slide. An “inkjet synthesizer” propels mole-
cular strands of DNA onto the surface of a
slide, “printing” arrays of DNA molecules
in a process not unlike the manner in
which an inkjet printer deposits ink onto
paper, forming distinct patterns of charac-
ters and images. 
Microarrays Demystified
DNA microarrays contain literally thou-
sands of unique DNA sequences, or
probes, which are deposited in an orderly
arrangement onto a solid substrate such as
a glass slide. Each probe corresponds to a
DNA sequence within one or more genes.
Microarrays give researchers a glimpse at
genetic activity within a cell by indicating
which genes are being expressed and to
what extent. Researchers then analyze the
microarrays with sophisticated software to
discover, for example, which genes con-
trol biologic processes, study toxic
responses within cells, or chart molecular
pathways to disease. All of this informa-
tion can point to possible new drugs to
treat disease. 
Such chips can be made in one of sever-
al ways. One method employs photolithog-
raphy, a method that is similar to that used
to manufacture electronic microchips, in
which a series of patterned masks and
chemical processing are used to build an
array of predetermined DNA sequences on
the chip, base by base. Other methods of
DNA deposition include flux spray, reagent
spotting, and the inkjet technique.
To analyze gene expression using such
microarrays, mRNA (or messenger RNA) is
first extracted from a cell or tissue culture,
then converted to short lengths of cDNA
(or complementary DNA). The cDNA is
then amplified—copied in an enzymatic
reaction using polymerase chain reaction,
or PCR—and tagged with a fluorescent
label. The pool of amplified sample cDNA
mixes and binds to complementary probe
DNA sequences on the microarray, a
process known as hybridization. A laser
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DNAs with fluorescent tags to generate sig-
nals of intensity in proportion to their origi-
nal abundance in the mRNA pool. Later,
these hybridization data are analyzed using a
sophisticated hardware/software system
called Rosetta Resolver™ to reveal gene
expression patterns.
FlexJet’s History
The FlexJet microarrays had their genesis
in work begun in the early 1990s by
Blanchard. Working at the California
Institute of Technology alongside Hood—
whose laboratory was well known for DNA
sequencing—Blanchard investigated the
possibility that nucleotides, or precursors
used to bind DNA molecules, could
replace the dyes in an inkjet and thus be
propelled through a nozzle onto a glass
slide. For decades inkjets had been used to
deposit precise amounts of dye onto specif-
ic locations on a piece of paper. Why not
co-opt that technology, he and his col-
leagues wondered, and adapt it to the syn-
thesis of genetic material on a glass slide? 
In time, the team took their research to
the University of Washington in Seattle,
where Hood was the founder and chairman
of the Department of Molecular Bio-
technology. While there, Hood and
Blanchard began to have conversations with
colleagues at the Fred Hutchinson Cancer
Research Center including center director
Leland Hartwell and Stephen Friend, who
led the center’s program in molecular phar-
macology. Hartwell and Friend were inter-
ested in the question of how arrays could be
used to follow the effects of compounds on
cells. Friend explains the collaboration by
saying, “We combined our interest in pat-
tern recognition and their flexible inkjet
technology.” 
Blanchard soon developed a prototype
model to prove that his original idea for
inkjet synthesis of DNA was possible. The
prototype incorporated an Epson printer
head and “was part robust machine and part
science project,” as Friend puts it. The
machine could synthesize long oligonu-
cleotides—or stretches of DNA—on a glass
slide with the same accuracy that an inkjet
printer could spit ink onto paper. 
According to Friend, it took about a
year to validate the commercial viability of
such a machine, and the FlexJet system was
on its way. That done, Rosetta chose not to
manufacture the arrays themselves. They
instead forged an alliance with Hewlett-
Packard’s tests and measurements sub-
sidiary, Agilent Technologies, which would
assume the role of manufacturing and mar-
keting the array system. (The Palo Alto,
California–based company became fully
independent of Hewlett-Packard in June
2000.) Since Rosetta’s FlexJet arrays com-
plement Agilent’s own DNA array technolo-
gy program, the two companies formed a
partnership. “We’ve been able to shift the
know-how, intelligence, and intellectual
property to Agilent,” Friend explains. “This
allows Rosetta to focus on how to interpret
the patterns that are projected into the
microarray.”
According to Wilson Woo, marketing
manager for Agilent’s bioscience products
division, his company has significantly
developed and enhanced the technology
through its manufacturing process. 
Flexible, Fast, and Specific 
The major advantages of FlexJet, accord-
ing to Friend, are its flexibility and its
specificity. “It allows very specific regions
of a gene to capture what’s going on in the
cell,” he says.
Woo agrees. “The advantage is, you can
custom-design what DNA goes onto the
glass slide,” he says. The process of probe
selection is software-driven; researchers can
program changes into the next phase of the
experiment without having to redesign the
entire array. This makes inkjet arrays ideal
for hypothesis-driven experiments: “You
form a hypothesis, do the experiment, find
out something different, then you can
change the design,” Woo says. 
Flexibility and reproducibility are two of
the reasons the FlexJet arrays hold so much
promise. Traditional DNA arrays—in which
cDNAs, or gene fragments, are placed onto
glass slides by hand—are expensive to make
and analyze in terms of the cost of both time
and materials. Such arrays require a
researcher to presynthesize tens of thousands
of fragments and then put them on the
slides. And any researcher who wants to
tweak the experiment a bit or change one of
the sequences must start over. “It’s expensive
to put down a different set [of gene frag-
ments],” Friend adds.
Photolithography offers an improvement
over that method, but it too has limitations.
For each nucleotide, four chromium masks
must be made. “You have to make a mask
for each new design process,” Friend says,
and that can be time-consuming.
By contrast, the inkjet arrays offer “fast
turnaround with custom DNA,” says Woo.
Fabricators can go from design to array
within a few days. Depending on the for-
mat, size, and labor required, Woo says, the
arrays can cost anywhere from a few hun-
dred to a little over a thousand dollars each. 
Another advantage this technique offers
is noncontact printing: the printer head
applies droplets of genetic material to the
substrate surface without actually touching
it. This provides a more uniform shape
than pin-spotting, a technique in which a
tiny pin touches the glass to apply the
cDNAs. This benefit, contends Woo, is
critical for achieving reliable data analysis.
Pin-spotting is also slower and consumes
more material, whereas inkjet arrays require
only a very small volume of genetic materi-
al. “We can print five times more microar-
rays using the same amount of genetic
material,” Woo says. 
Drug and Disease Discoveries
Drug discovery promises to be one of the
most useful applications of the FlexJet sys-
tem. With fewer samples and less testing, it
is now possible to build up a database of
known areas within genes that are respon-
sible for certain functions, an advantage
that promises to be very useful in making
new drugs. Inkjet arrays have been used to
analyze the effects on DNA of compounds
from cadmium to phenobarbitol, pesticides
to heavy metals. 
Working as a molecular geneticist in the
early 1990s, Friend became aware of lots of
discoveries being made about genes that are
important to disease, but, he says, “were so
slow to reach the patient.” That didn’t sit
well with Friend, who is also a pediatric
oncologist. Friend says the force that propels
Rosetta’s work is the quest to use this tech-
nology to benefit patients.
The same motivation drives Jerry Radich
and his fellow researchers at the Fred
Hutchinson Cancer Research Center—a
center known for pioneering cancer treat-
ments, including the first bone marrow
transplant. Radich’s team, which works in
the Clinical Research Division of the cen-
ter’s Program in Genetics/Genomics, is
using FlexJet microarrays in looking for
genes involved in the progression of chronic
myeloid leukemia (CML) to pinpoint better
treatments for leukemia patients. 
According to Radich, the disease pro-
gresses from the chronic phase into an accel-
erated phase, and then into the blast crisis
phase, the terminal phase of the disease dur-
ing which it has the greatest resistance to
treatment. It is critical to administer
chemotherapy well before this final, acute
phase. However, the first phase—the chron-
ic phase—can last anywhere from 6 months
to 15 years, making it difficult to predict
when a patient is about to progress to the
next, more severe phase of the disease. So
Radich and his colleagues want to compare
the expression of genes in the chronic phase
with those in the blast crisis phase.
“We don’t understand what drives the
molecular clock in CML; no one under-
stands the genetic progression during the
chronic phase,” Radich says. He believes
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other malignancies, as well as guide future
medical diagnostics. He hopes one day to
have a genetic test that can be administered
during the early phase of CML to show
whether a leukemia patient will be likely to
experience a shorter or longer chronic phase.
This information would help physicians
time chemotherapy treatments for maxi-
mum effectiveness.
So far, Radich’s preliminary data have
shown clear changes in the gene expression
profiles that occur relatively early in the pro-
gression of the disease, results he calls
“extremely promising.” Using the FlexJet
microarrays, he has compared samples from
approximately 20 chronic-phase patients
with samples from 10 blast crisis–phase
patients. He plans to analyze and compare
samples from 100 more patients to ensure
that the results gained are statistically robust. 
Transforming Science
The dizzying possibilities offered by such
sophisticated microarrays call into question
some long-accepted conventions in the
world of science. In the past, researchers
have tended to conduct experiments,
derive conclusions, then go on to the next
project, sometimes without saving data
that might prove quite valuable to the next
researcher down the line. Friend believes
scientists haven’t yet learned how to con-
nect with each other to create core databas-
es accessible to others who are interested in
similar questions. “There needs to be a
coordinated effort. Scientists have not
found rewards sufficient to make them
eager to link together,” Friend laments.
The unfortunate result, he says, is that “a
lot of the power of technology gets reduced
simply to being a separate finding.” 
Still, Friend says, using arrays in general
is transforming the way scientists approach
their research. “Biology has been done by
asking very specific questions about ‘my
favorite gene,’” Friend says. Asking such spe-
cific questions yields information about one
small area of interest. Instead of performing
experiment after experiment—turning up
one genetic clue at a time—scientists can
capitalize on array technology to yield a
whole set of potentially meaningful genetic
clues at one time.
“Arrays have the ability to sense the
whole genome, and get [feedback] on all the
information in a cell,” Friend explains.
“This allows you to see unanticipated or
unwanted [cellular] effects. This is a signifi-
cant advantage over the old methods of ana-
lyzing compounds and patient samples.”
While it is certainly impressive to have
the capability to learn so much about one
cell in one fell swoop, the questions arise
whether at some point so much information
is too much, and how much of it is truly
useful. Friend admits that making sense of
the overwhelming quantity of gene expres-
sion data obtained from a single microarray
does present a dilemma. “There are 50,000
dimensions of information for one cell,”
Friend concedes. “The challenge will be in
developing tools that allow one to extract
that information.”
Radich echoes this concern: “How do
you make sense of the data? How do you
extract the information from the noise?”
Still, he is enthusiastic about the promise
the FlexJet microarrays show in his research
on leukemia treatments. “It’s changed the
way we look at things,” he reflects. With
the microarray technology, scientists not
only find answers to their initial queries,
but they also find patterns in genes that
they weren’t looking for at all. Such discov-
eries could lead down new roads toward
altogether new destinations and yield
important answers to questions scientists
haven’t yet thought of posing. “The poten-
tial is fantastic,” Radich says. “We’ll proba-
bly understand what the patterns of . . .
genes mean before we actually find out how
they work together.” 
Jennifer Medlin
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researchers measure and analyze gene
expression faster, more economically, and
with greater precision than ever before
possible. These small glass slides may rev-
olutionize the field of toxicogenomics,
helping scientists target new drugs, dis-
cover gene functions, determine biologic
pathways, and better understand illnesses
such as cancer, cystic fibrosis, and cardio-
vascular disease at the molecular level.
The FlexJet™ system, as the microar-
ray product is known, was pioneered by the
group of scientists who founded Rosetta
Inpharmatics—Stephen Friend, Leland
Hartwell, Leroy Hood, and Jasper Rine—
along with Alan Blanchard, who heads
Rosetta’s FlexJet technology development
team. The system combines modern print-
ing technology with DNA synthesis tech-
niques to print tiny arrays of thousands of
different gene sequences onto a single glass
slide. An “inkjet synthesizer” propels mole-
cular strands of DNA onto the surface of a
slide, “printing” arrays of DNA molecules
in a process not unlike the manner in
which an inkjet printer deposits ink onto
paper, forming distinct patterns of charac-
ters and images. 
Microarrays Demystified
DNA microarrays contain literally thou-
sands of unique DNA sequences, or
probes, which are deposited in an orderly
arrangement onto a solid substrate such as
a glass slide. Each probe corresponds to a
DNA sequence within one or more genes.
Microarrays give researchers a glimpse at
genetic activity within a cell by indicating
which genes are being expressed and to
what extent. Researchers then analyze the
microarrays with sophisticated software to
discover, for example, which genes con-
trol biologic processes, study toxic
responses within cells, or chart molecular
pathways to disease. All of this informa-
tion can point to possible new drugs to
treat disease. 
Such chips can be made in one of sever-
al ways. One method employs photolithog-
raphy, a method that is similar to that used
to manufacture electronic microchips, in
which a series of patterned masks and
chemical processing are used to build an
array of predetermined DNA sequences on
the chip, base by base. Other methods of
DNA deposition include flux spray, reagent
spotting, and the inkjet technique.
To analyze gene expression using such
microarrays, mRNA (or messenger RNA) is
first extracted from a cell or tissue culture,
then converted to short lengths of cDNA
(or complementary DNA). The cDNA is
then amplified—copied in an enzymatic
reaction using polymerase chain reaction,
or PCR—and tagged with a fluorescent
label. The pool of amplified sample cDNA
mixes and binds to complementary probe
DNA sequences on the microarray, a
process known as hybridization. A laser
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DNAs with fluorescent tags to generate sig-
nals of intensity in proportion to their origi-
nal abundance in the mRNA pool. Later,
these hybridization data are analyzed using a
sophisticated hardware/software system
called Rosetta Resolver™ to reveal gene
expression patterns.
FlexJet’s History
The FlexJet microarrays had their genesis
in work begun in the early 1990s by
Blanchard. Working at the California
Institute of Technology alongside Hood—
whose laboratory was well known for DNA
sequencing—Blanchard investigated the
possibility that nucleotides, or precursors
used to bind DNA molecules, could
replace the dyes in an inkjet and thus be
propelled through a nozzle onto a glass
slide. For decades inkjets had been used to
deposit precise amounts of dye onto specif-
ic locations on a piece of paper. Why not
co-opt that technology, he and his col-
leagues wondered, and adapt it to the syn-
thesis of genetic material on a glass slide? 
In time, the team took their research to
the University of Washington in Seattle,
where Hood was the founder and chairman
of the Department of Molecular Bio-
technology. While there, Hood and
Blanchard began to have conversations with
colleagues at the Fred Hutchinson Cancer
Research Center including center director
Leland Hartwell and Stephen Friend, who
led the center’s program in molecular phar-
macology. Hartwell and Friend were inter-
ested in the question of how arrays could be
used to follow the effects of compounds on
cells. Friend explains the collaboration by
saying, “We combined our interest in pat-
tern recognition and their flexible inkjet
technology.” 
Blanchard soon developed a prototype
model to prove that his original idea for
inkjet synthesis of DNA was possible. The
prototype incorporated an Epson printer
head and “was part robust machine and part
science project,” as Friend puts it. The
machine could synthesize long oligonu-
cleotides—or stretches of DNA—on a glass
slide with the same accuracy that an inkjet
printer could spit ink onto paper. 
According to Friend, it took about a
year to validate the commercial viability of
such a machine, and the FlexJet system was
on its way. That done, Rosetta chose not to
manufacture the arrays themselves. They
instead forged an alliance with Hewlett-
Packard’s tests and measurements sub-
sidiary, Agilent Technologies, which would
assume the role of manufacturing and mar-
keting the array system. (The Palo Alto,
California–based company became fully
independent of Hewlett-Packard in June
2000.) Since Rosetta’s FlexJet arrays com-
plement Agilent’s own DNA array technolo-
gy program, the two companies formed a
partnership. “We’ve been able to shift the
know-how, intelligence, and intellectual
property to Agilent,” Friend explains. “This
allows Rosetta to focus on how to interpret
the patterns that are projected into the
microarray.”
According to Wilson Woo, marketing
manager for Agilent’s bioscience products
division, his company has significantly
developed and enhanced the technology
through its manufacturing process. 
Flexible, Fast, and Specific 
The major advantages of FlexJet, accord-
ing to Friend, are its flexibility and its
specificity. “It allows very specific regions
of a gene to capture what’s going on in the
cell,” he says.
Woo agrees. “The advantage is, you can
custom-design what DNA goes onto the
glass slide,” he says. The process of probe
selection is software-driven; researchers can
program changes into the next phase of the
experiment without having to redesign the
entire array. This makes inkjet arrays ideal
for hypothesis-driven experiments: “You
form a hypothesis, do the experiment, find
out something different, then you can
change the design,” Woo says. 
Flexibility and reproducibility are two of
the reasons the FlexJet arrays hold so much
promise. Traditional DNA arrays—in which
cDNAs, or gene fragments, are placed onto
glass slides by hand—are expensive to make
and analyze in terms of the cost of both time
and materials. Such arrays require a
researcher to presynthesize tens of thousands
of fragments and then put them on the
slides. And any researcher who wants to
tweak the experiment a bit or change one of
the sequences must start over. “It’s expensive
to put down a different set [of gene frag-
ments],” Friend adds.
Photolithography offers an improvement
over that method, but it too has limitations.
For each nucleotide, four chromium masks
must be made. “You have to make a mask
for each new design process,” Friend says,
and that can be time-consuming.
By contrast, the inkjet arrays offer “fast
turnaround with custom DNA,” says Woo.
Fabricators can go from design to array
within a few days. Depending on the for-
mat, size, and labor required, Woo says, the
arrays can cost anywhere from a few hun-
dred to a little over a thousand dollars each. 
Another advantage this technique offers
is noncontact printing: the printer head
applies droplets of genetic material to the
substrate surface without actually touching
it. This provides a more uniform shape
than pin-spotting, a technique in which a
tiny pin touches the glass to apply the
cDNAs. This benefit, contends Woo, is
critical for achieving reliable data analysis.
Pin-spotting is also slower and consumes
more material, whereas inkjet arrays require
only a very small volume of genetic materi-
al. “We can print five times more microar-
rays using the same amount of genetic
material,” Woo says. 
Drug and Disease Discoveries
Drug discovery promises to be one of the
most useful applications of the FlexJet sys-
tem. With fewer samples and less testing, it
is now possible to build up a database of
known areas within genes that are respon-
sible for certain functions, an advantage
that promises to be very useful in making
new drugs. Inkjet arrays have been used to
analyze the effects on DNA of compounds
from cadmium to phenobarbitol, pesticides
to heavy metals. 
Working as a molecular geneticist in the
early 1990s, Friend became aware of lots of
discoveries being made about genes that are
important to disease, but, he says, “were so
slow to reach the patient.” That didn’t sit
well with Friend, who is also a pediatric
oncologist. Friend says the force that propels
Rosetta’s work is the quest to use this tech-
nology to benefit patients.
The same motivation drives Jerry Radich
and his fellow researchers at the Fred
Hutchinson Cancer Research Center—a
center known for pioneering cancer treat-
ments, including the first bone marrow
transplant. Radich’s team, which works in
the Clinical Research Division of the cen-
ter’s Program in Genetics/Genomics, is
using FlexJet microarrays in looking for
genes involved in the progression of chronic
myeloid leukemia (CML) to pinpoint better
treatments for leukemia patients. 
According to Radich, the disease pro-
gresses from the chronic phase into an accel-
erated phase, and then into the blast crisis
phase, the terminal phase of the disease dur-
ing which it has the greatest resistance to
treatment. It is critical to administer
chemotherapy well before this final, acute
phase. However, the first phase—the chron-
ic phase—can last anywhere from 6 months
to 15 years, making it difficult to predict
when a patient is about to progress to the
next, more severe phase of the disease. So
Radich and his colleagues want to compare
the expression of genes in the chronic phase
with those in the blast crisis phase.
“We don’t understand what drives the
molecular clock in CML; no one under-
stands the genetic progression during the
chronic phase,” Radich says. He believes
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have a genetic test that can be administered
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whether a leukemia patient will be likely to
experience a shorter or longer chronic phase.
This information would help physicians
time chemotherapy treatments for maxi-
mum effectiveness.
So far, Radich’s preliminary data have
shown clear changes in the gene expression
profiles that occur relatively early in the pro-
gression of the disease, results he calls
“extremely promising.” Using the FlexJet
microarrays, he has compared samples from
approximately 20 chronic-phase patients
with samples from 10 blast crisis–phase
patients. He plans to analyze and compare
samples from 100 more patients to ensure
that the results gained are statistically robust. 
Transforming Science
The dizzying possibilities offered by such
sophisticated microarrays call into question
some long-accepted conventions in the
world of science. In the past, researchers
have tended to conduct experiments,
derive conclusions, then go on to the next
project, sometimes without saving data
that might prove quite valuable to the next
researcher down the line. Friend believes
scientists haven’t yet learned how to con-
nect with each other to create core databas-
es accessible to others who are interested in
similar questions. “There needs to be a
coordinated effort. Scientists have not
found rewards sufficient to make them
eager to link together,” Friend laments.
The unfortunate result, he says, is that “a
lot of the power of technology gets reduced
simply to being a separate finding.” 
Still, Friend says, using arrays in general
is transforming the way scientists approach
their research. “Biology has been done by
asking very specific questions about ‘my
favorite gene,’” Friend says. Asking such spe-
cific questions yields information about one
small area of interest. Instead of performing
experiment after experiment—turning up
one genetic clue at a time—scientists can
capitalize on array technology to yield a
whole set of potentially meaningful genetic
clues at one time.
“Arrays have the ability to sense the
whole genome, and get [feedback] on all the
information in a cell,” Friend explains.
“This allows you to see unanticipated or
unwanted [cellular] effects. This is a signifi-
cant advantage over the old methods of ana-
lyzing compounds and patient samples.”
While it is certainly impressive to have
the capability to learn so much about one
cell in one fell swoop, the questions arise
whether at some point so much information
is too much, and how much of it is truly
useful. Friend admits that making sense of
the overwhelming quantity of gene expres-
sion data obtained from a single microarray
does present a dilemma. “There are 50,000
dimensions of information for one cell,”
Friend concedes. “The challenge will be in
developing tools that allow one to extract
that information.”
Radich echoes this concern: “How do
you make sense of the data? How do you
extract the information from the noise?”
Still, he is enthusiastic about the promise
the FlexJet microarrays show in his research
on leukemia treatments. “It’s changed the
way we look at things,” he reflects. With
the microarray technology, scientists not
only find answers to their initial queries,
but they also find patterns in genes that
they weren’t looking for at all. Such discov-
eries could lead down new roads toward
altogether new destinations and yield
important answers to questions scientists
haven’t yet thought of posing. “The poten-
tial is fantastic,” Radich says. “We’ll proba-
bly understand what the patterns of . . .
genes mean before we actually find out how
they work together.” 
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